Tip of the Iceberg: Assessing the Global Socioeconomic Costs of Alzheimer’s Disease and Related Dementias and Strategic Implications for Stakeholders
Open accessThe DOI matches its Crossref record; 133 of the 133 references it cites were found in a registry or an index.
Abstract
While it is generally understood that Alzheimer's disease (AD) and related dementias (ADRD) is one of the costliest diseases to society, there is widespread concern that researchers and policymakers are not comprehensively capturing and describing the full scope and magnitude of the socioeconomic burden of ADRD. This review aimed to 1) catalogue the different types of AD-related socioeconomic costs described in the literature; 2) assess the challenges and gaps of existing approaches to measuring these costs; and 3) analyze and discuss the implications for stakeholders including policymakers, healthcare systems, associations, advocacy groups, clinicians, and researchers looking to improve the ability to generate reliable data that can guide evidence-based decision making. A centrally emergent theme from this review is that it is challenging to gauge the true value of policies, programs, or interventions in the ADRD arena given the long-term, progressive nature of the disease, its insidious socioeconomic impact beyond the patient and the formal healthcare system, and the complexities and current deficiencies (in measures and real-world data) in accurately calculating the full costs to society. There is therefore an urgent need for all stakeholders to establish a common understanding of the challenges in evaluating the full cost of ADRD and define approaches that allow us to measure these costs more accurately, with a view to prioritizing evidence-based solutions to mitigate this looming public health crisis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Global economic costs of ADRD are projected to double from $1 trillion to $2 trillion (USD) in the next decade alone (e.g., from 2018 to 2030) [114,115].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Self-citationDementia prevention, intervention, and care
Livingston, G., Sommerlad, A., Orgeta, V., Costafreda, S. G., Huntley, J., Ames, D., Ballard, C., Banerjee, S., Burns, A., Cohen-Mansfield, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31363-6 · Cited by 6,072 · cited 1×
“Moreover, despite improvements in the quality of care for patients and the identification of several potentially modifiable risk factors [118], the causal mechanisms of ADRD are complex, multifactorial and not fully elucidated, and no disease-modifying intervention is available to delay, halt, or reverse the underlyin…”
BackgroundSelf-citation2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
Potential for primary prevention of Alzheimer's disease: an analysis of population-based data
Norton, S., Matthews, F. E., Barnes, D. E., Yaffe, K., & Brayne, C. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70136-x · Cited by 2,466
2019 Alzheimer’s disease facts and figures.
Alzheimer's Association (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.01.010 · Cited by 2,461
Nichols, E., Szoeke, C. E. I., Vollset, S. E., Abbasi, N., Abd-Allah, F., Abdela, J., Aichour, M. T. E., Akinyemi, R. O., Alahdab, F., Asgedom, S. W., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30403-4 · Cited by 2,412 · cited 1×
“dency among older adults worldwide [1], having a significant impact not only on individuals but also on their families, communities, and societies.”
Background(2015) · HAL · Cited by 2,238
Preclinical Alzheimer’s Disease: Definition, Natural History, and Diagnostic Criteria
Dubois, B., Hampel, H., Feldman, H. H., Scheltens, P., Aisen, P., Andrieu, S., Bakardjian, H., Benali, H., Bertram, L., Blennow, K., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.002 · Cited by 1,925
Self-citation2018 Alzheimer's disease facts and figures
Alzheimer's Association (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.001 · Cited by 1,912
Defeating Alzheimer's disease and other dementias: a priority for European science and society
Winblad, B., Amouyel, P., Andrieu, S., Ballard, C., Brayne, C., Brodaty, H., Cedazo-Minguez, A., Dubois, B., Edvardsson, D., Feldman, H., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00062-4 · Cited by 1,676 · cited 5×
“, English Longitudinal Study on Aging, Swedish National Study on Aging) and may supply some of these data, these studies have generally been focused on patients with a dementia diagnosis and rely on a limited range of assessments [4, 28].”
BackgroundInfluentialSelf-citation
Research works printed but not linked: 1
- World Health Organization. First WHO Ministerial Conference on Global Action Against Dementia.
Cited by
Items 101–200 of 215
Unpaid Caregiver Costs in Canada: A Systematic Review
Marani, H., & Peckham, A. (2023) · Home Health Care Management & Practice · doi:10.1177/10848223231169504 · Cited by 11
“42,43 These deficiencies in data capture undermine the full financial impact of these costs on caregivers, and mask the economic and societal impact at large.”
BackgroundSwanson, L. M., Hood, M. M., Thurston, R. C., Butters, M. A., Kline, C. E., Kravitz, H. M., Avis, N. E., Neal-Perry, G. S., Joffe, H., Harlow, S. D., et al. (2025) · SLEEP · doi:10.1093/sleep/zsaf041 · Cited by 10
Modelling the value of innovative treatments for Alzheimer’s disease in the United States
Makin, C., Neumann, P. J., Peschin, S., & Goldman, D. P. (2021) · Journal of Medical Economics · doi:10.1080/13696998.2021.1927747 · Cited by 11
Design and Development of a Community-Based, Interdisciplinary, Collaborative Dementia Care Program
Goldfarb, D., Allen, A. M., Nisson, L. E., Petitti, D. B., Saner, D., Langford, C., Burke, W. J., Reiman, E. M., Atri, A., & Tariot, P. N. (2021) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2021.10.014 · Cited by 11
Self-citationDominguez, J. C., Yu, J. R. T., Guzman, M. F. D., Ampil, E. R., Guevarra, A. C., Joson, M. L. C., Reandelar, M., Martinez, M., Ligsay, A. D., Ocampo, F. F., et al. (2022) · International Journal of Alzheimer s Disease · doi:10.1155/2022/9960832 · Cited by 14
“Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that commonly affects the elderly [1], accounting for up to 80% of dementias, [2] with a heavy socio-economic burden [3, 4].”
BackgroundHilsabeck, R. C., Lacritz, L. H., Colvin, M. K., Espe‐Pfeifer, P., Sperling, S. A., Arnett, P. A., & Perry, W. (2022) · Policy Insights from the Behavioral and Brain Sciences · doi:10.1177/23727322221110261 · Cited by 14
“…professionals, direct care providers, and family caregivers, can help minimize stress, decrease duplication of services, reduce costs, and improve quality of care (Aguirre et al., 2022; Amjad et al., 2016; Boustani et al., 2011; Callahan et al., 2006; Galvin et al., 2014; Reuben et al., 2019).”
BackgroundKunicki, Z. J., Frietchen, R. E., McGeary, J. E., Jiang, L., Duprey, M. S., Bayer, T., Singh, M., Primack, J. M., Kelso, C. M., Wu, W., et al. (2023) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2023.01.026 · Cited by 11
Hermosura, A. H., Noonan, C., Fyfe‐Johnson, A. L., Seto, T. B., Kaholokula, J. K., & MacLehose, R. F. (2020) · Journal of Aging and Health · doi:10.1177/0898264320945177 · Cited by 11
“, inability to maintain employment) and reduced quality of life for both caregivers and patients (El-Hayek et al., 2019).”
BackgroundInfluentialMODELLING THE PAN-EUROPEAN ECONOMIC BURDEN OF ALZHEIMER'S DISEASE
Martins, R., Urbich, M., Brännvall, K., Gianinazzi, M., Ching, J. E., Khoury, C. P., & El-Hayek, Y. H. (2022) · Journal of Aging Research and Lifestyle · doi:10.14283/jarlife.2022.7 · Cited by 11
Self-citationJönsson, L., Ivkovic, M., Atri, A., Handels, R. L. H., Gustavsson, A., Hahn‐Pedersen, J. H., León, T., Lilja, M., Gundgaard, J., & Rakêt, L. L. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01413-y · Cited by 11
“Alzheimer’s disease (AD) is a debilitating neurodegenerative disorder and a primary cause of dementia resulting in reduced life expectancy [1, 2], loss of function and autonomy [1, 3], impaired quality of life (QoL) [4], care partner burden [5–7], and high costs to society [8, 9].”
BackgroundSelf-citationBen‐Azu, B., Oghorodi, A. M., Oritsemuelebi, B., & Chidebe, E. O. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.112517 · Cited by 10
Marani, H., Allin, S. M., McKay, S. M., & Marchildon, G. P. (2023) · Health Services Insights · doi:10.1177/11786329221144889 · Cited by 9
Moebius, H. J., & Church, K. J. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-220871 · Cited by 10
Bayat, S., Roe, C. M., Schindler, S. E., Murphy, S. A., Doherty, J. M., Johnson, A. M., Walker, A. I. B., Ances, B. M., Morris, J. C., & Babulal, G. M. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221268 · Cited by 11
“Alzheimer’s disease (AD), the most common type of dementia, is a progressive, debilitating disease and has emerged as an urgent public health crisis given the growing numbers of older adults worldwide [1].”
Bannon, S. M., Brewer, J. R., Ahmad, N., Cornelius, T. M., Jackson, J., Parker, R. A., Dams-O’Connor, K., Dickerson, B. C., Ritchie, C. S., & Vranceanu, A. (2023) · JMIR Research Protocols · doi:10.2196/45532 · Cited by 10
Mar, J., Gorostiza, A., Ibarrondo, O., Larrañaga, I., Arrospide, A., Martínez‐Lage, P., & Soto‐Gordoa, M. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00737-9 · Cited by 8
Mapping Long-Term Care in Jamaica: Addressing an Ageing Population
Govia, I., Robinson, J. N., Amour, R., Stubbs, M., Lorenz‐Dant, K., Comas‐Herrera, A., & Knapp, M. R. J. (2021) · Sustainability · doi:10.3390/su13148101 · Cited by 9
“Similar to what has been noted in other contexts [22,23], those who are able to pay for care have drawn from their individual and family resources (such as family members providing care, personal income, savings, and assets) and voluntary private insurance schemes.”
BackgroundResultInfluentialIkeuchi, T., Yano, Y., Sato, W., Morikawa, F., Toru, S., Nishimura, C., MIYAZAWA, N., Kuroha, Y., Koike, R., Tanaka, S., et al. (2022) · Nutrients · doi:10.3390/nu14030637 · Cited by 10
“Alzheimer’s disease (AD) is a neurodegenerative condition that is highly prevalent in old age [1] and has a significant socioeconomic impact [2].”
BackgroundKubis-Kubiak, A., Wiatrak, B., & Piwowar, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115526 · Cited by 9
“The growing occurrence of both diabetes and dementia leading to AD is becoming a social and economic challenge worldwide [8,9].”
BackgroundLing, T., Chang, C., Li, C., Sung, J., Sun, C., Tsai, K., Cheng, Y., Wu, J., Kuo, Y.-T., & Chang, Y. (2021) · European Journal of Neurology · doi:10.1111/ene.15123 · Cited by 11
“It is estimated that currently approximately 50 million people have dementia worldwide, and the number is projected to rise to 130 million by 2050 [2], becoming a huge burden on caregivers and the healthcare system [3,4].”
BackgroundAngrist, M. H., Yang, A., Kantor, B., & Chiba‐Falek, O. (2020) · Life Sciences Society and Policy · doi:10.1186/s40504-020-00106-2 · Cited by 8
The formal care costs of dementia: a longitudinal study using Swedish register data
Zilling, J., Gerdtham, U., Jarl, J., Saha, S., & Persson, S. (2024) · The European Journal of Health Economics · doi:10.1007/s10198-024-01707-w · Cited by 9
“Dementia diseases stand among the costliest diseases and exceed the costs of cancer and heart disease combined [1, 2].”
Hart, D. M., Leggins, B., Sanches, C., Guterman, E. L., & Chiong, W. (2025) · The Gerontologist · doi:10.1093/geront/gnaf092 · Cited by 8
Atri, A., Apostolova, L. G., Iwata, A., Wessels, A. M., Atkins, A. S., Lu, M., Ye, W., Ryan, S., & Doty, E. G. (2026) · Neurology Clinical Practice · doi:10.1212/cpj.0000000000200621 · Cited by 9
Self-citationCost of Patients with Alzheimer’s Disease in Spain According to Disease Severity
Maldonado, L. G., de Mora-Figueroa, R., López-Angarita, A., Maravilla‐Herrera, P., & Merino, M. (2023) · PharmacoEconomics - Open · doi:10.1007/s41669-023-00451-w · Cited by 10
“It is not surprising that AD carries heavy consequences on the caregiver´s quality of life and health [21–23].”
BackgroundMonfared, A. A. T., Hummel, N., Chandak, A. N., Khachatryan, A., & Zhang, Q. (2023) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2023.23013 · Cited by 10
Wertman, E. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13144202 · Cited by 6
“Dementia and predementia are highly prevalent [1–4], with high personal, caregiver, societal, and economic costs [5,6].”
BackgroundBannon, S. M., McCage, S., Walker, K., Brewer, J. R., Ahmad, N., Cornelius, T. M., Parker, R. A., Dams-O’Connor, K., Dickerson, B. C., Ritchie, C. S., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251332658 · Cited by 8
Chen, Y., Su, Y., Su, Y., Chen, K., Atri, A., Caselli, R. J., Reiman, E. M., Wang, Y., & Initiative, T. A. D. N. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231162 · Cited by 6
“However, over that last century, Alzheimer’s disease (AD) has been recognized as a major global health concern that is primarily causing and contributing to cognitive impairment and dementia worldwide with increasing burden and costs [2, 3].”
Self-citationThe NGF Metabolic Pathway: New Opportunities for Biomarker Research and Drug Target Discovery
Pentz, R., & Iulita, M. F. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-74046-7_4 · Cited by 9
Won, J., Tomoto, T., Tarumi, T., Rodrigue, K. M., Kennedy, K. M., Park, D. C., & Zhang, R. (2025) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00429.2024 · Cited by 6
Predictive factors on caregiver burden in caregivers of individuals with cognitive impairment
Lee, M., & Williams, I. C. (2022) · International Journal of Care Coordination · doi:10.1177/20534345221148281 · Cited by 9
“As a result, there is an even more critical need to better define and measure the hidden costs among caregivers that are not currently being assessed.(2) Cognitive impairment most often presents with memory loss, which is the first and the most commonly recognized symptom by older adults and their caregivers.”
BackgroundCallahan, L. F., Samsell, B. J., DiBenedetti, D. B., Frangiosa, T. L., Slota, C., Biggar, V. S., Paulsen, R., Lappin, D. R., Herring, W. L., & DeMuro, C. (2023) · Neurology and Therapy · doi:10.1007/s40120-023-00558-6 · Cited by 5
“The socioeconomic impact and value of non-professional caregiving can be challenging to calculate due to the complex nature of AD and lack of sufficient real world data [13].”
BackgroundMarešová, P., Komárková, L., Kuhnova, J., Cimler, R., Pazitny, P., Kandilaki, D., Musílek, K., Truhlářová, Z., Zemek, F., & Kuča, K. (2020) · Healthcare · doi:10.3390/healthcare8040433 · Cited by 7
“However, all values focusing on the specification of the economic burden must be interpreted in the context that the person diagnosed with AD usually has additional physical and mental diagnoses [49] affecting their overall quality of life.”
BackgroundExcess costs of dementia in old age (85+) in Germany: Results from the AgeCoDe-AgeQualiDe study
Neubert, L., König, H., Löbner, M., Luppa, M., Pentzek, M., Fuchs, A., Weeg, D., Bickel, H., Oey, A., Wiese, B., et al. (2021) · The Journal of the Economics of Ageing · doi:10.1016/j.jeoa.2021.100346 · Cited by 5
Vesikansa, A., Halminen, O., Mehtälä, J., Hörhammer, I., Mikkola, T., Ylisaukko-Oja, T., & Linna, M. (2022) · European Journal of Health Economics · doi:10.1007/s10198-022-01553-8 · Cited by 4
Hosseini-Kivanani, N., Salobrar‐García, E., Elvira‐Hurtado, L., Salas, M., Schommer, C., & Leiva, L. A. (2024) · IEEE International Conference on eScience · doi:10.1109/e-science62913.2024.10678661 · Cited by 4
“Furthermore, the availability of specific diagnostic tests can be constrained by factors such as economic limitations, healthcare infrastructure, or geographical location [6].”
BackgroundLazo‐Porras, M., Tateishi-Serruto, F. J., Butler, C., Cuba-Fuentes, M. S., Rossini-Vilchez, D., Pérez-León, S., Lúcar-Flores, M., Miranda, J. J., Bernabé‐Ortiz, A., Diez‐Canseco, F., et al. (2025) · JMIR Research Protocols · doi:10.2196/60296 · Cited by 6
“Carers are 4 times more likely to experience depression and 3 times more likely to experience anxiety [49,50].”
Gutiérrez, R. M. P., Gómez, J. T., Flores, J. M. M., Téllez, M. D. L. L. C., & Muñiz-Ramírez, A. (2025) · Pharmaceuticals · doi:10.3390/ph18091391 · Cited by 6
Custo e Carga da Doença de Alzheimer nos Idosos em Portugal
Costa, J. N. (2021) · Sinapse · doi:10.46531/sinapse/ao/210055/2021 · Cited by 16
Pilozzi, A. R., Carro, C., Whalen, M. J., & Huang, X. (2020) · Exon Publications eBooks · doi:10.36255/exonpublications.alzheimersdisease.2020.ch8 · Cited by 9
“AD has a substantial economic impact, with projections indicating the global cost of dementia could balloon to 2 trillion US dollars by 2030 (2).”
BackgroundBermejo, L. M., González-Becerra, M. J., Barrios-Fernández, S., Mota, S. P., Jerez-Barroso, M. D. R., Martínez, J. A. F., Lantarón, B. S., Muñoz, D., Martín-Bermúdez, N., Ortés-Gómez, R., et al. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph192215243 · Cited by 7
Lewis, E. D., Apostol, M., Langston, J., Parker, A., & Evans, M. (2023) · Applied Sciences · doi:10.3390/app13052818 · Cited by 4
Hernández-Pinilla, A., Clua‐Espuny, J. L., Satué-Gracia, E. M., Pallejà-Millán, M., & Martín‐Luján, F. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-080736 · Cited by 4
Won, J., Tarumi, T., Tomoto, T., Shan, K., Rodrigue, K. M., Kennedy, K. M., Park, D. C., & Zhang, R. (2025) · GeroScience · doi:10.1007/s11357-025-01664-z · Cited by 3
Epidemiological and economic burden of dementia in the Middle East and North African region
Qadi, N., Alkhodair, Y., Alshammari, W., & AlDakheel, A. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251378454 · Cited by 3
Vislapuu, M., Berge, L. I., Angeles, R. C., Kjerstad, E., Mannseth, J., Achterberg, W. P., & Husebo, B. S. (2022) · BMC Health Services Research · doi:10.1186/s12913-022-08675-y · Cited by 7
Bradley, D., Harrison, J., Goodall, M., & Dobrashian, R. (2023) · International Journal for Advancing Practice · doi:10.12968/ijap.2023.1.3.146 · Cited by 3
“…2.09 million in 2051 (Prince et al. 2014) With an ageing population, dementia is a public health concern and the anticipated increase in people being diagnosed will likely impact the health and social care system and cause a significant global socio-Europe economic burden (El-Hayek et al. 2019).”
BackgroundInfluentialA review of dairy food intake for improving health among black geriatrics in the US
Mitchell, E. P., Comerford, K. B., Knight, M. G., McKinney, K. H., & Lawson, Y. (2024) · Journal of the National Medical Association · doi:10.1016/j.jnma.2024.01.017 · Cited by 3
Linking genomic and proteomic signatures to brain amyloid burden: insights from GR@ACE/DEGESCO
Puerta, R., de Rojas, I., García‐González, P., Olivé, C., Sotolongo‐Grau, Ó., García‐Sánchez, A., García‐Gutiérrez, F., Montrreal, L., Tartari, J. P., Sanabria, Á., et al. (2025) · Functional & Integrative Genomics · doi:10.1007/s10142-025-01581-6 · Cited by 4
“AD is a growing epidemic with an expected doubling of annual new diagnosis in the next 20 years prevalence and a major socioeconomic impact with a projected direct economic cost of $2 trillion by 2030 (Alzheimer’s Association 2022; El-Hayek et al. 2019; Nandi et al. 2022).”
Economic Evaluation of Lecanemab for Early Symptomatic Alzheimer's Disease in South Korea
Shin, S., Kim, M., & Hong, S. H. (2025) · PharmacoEconomics - Open · doi:10.1007/s41669-025-00593-z · Cited by 8
Bannon, S. M., Brewer, J. R., Cornelius, T. M., Jackson, J., Parker, R. A., Dams-O’Connor, K., Dickerson, B. C., Ritchie, C. S., & Vranceanu, A. (2023) · JMIR Research Protocols · doi:10.2196/45533 · Cited by 5
“By 2030, over 78 million individuals will be living with ADRD, leading to global health care costs of over US $2.8 trillion [1,2].”
InfluentialPreclinical Dementia and Economic Well-Being Trajectories of Racially Diverse Older Adults
Mudražija, S., Palms, J. D., Lee, J. H., Maher, A., Zahodne, L. B., & Chopik, W. J. (2024) · Journal of Aging and Health · doi:10.1177/08982643241237292 · Cited by 3
“We also see these long-standing economic disparities extend into the preclinical phase of ADRD, where they could have substantial impact on receiving a formal diagnosis, accessing high-quality dementia care, and buffering dementia-related expenses.”
InfluentialMeaningful benefit of disease‐modifying treatment: Evaluating changes in health‐related resource use
Zhu, C. W., & Sano, M. (2024) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12455 · Cited by 5
Hao, Y., Shen, X. Y., Liu, J., Cai, Z., Wang, X., Yang, Z., Chen, F., Dong, B., Wang, R., Du, X., et al. (2024) · Nano Letters · doi:10.1021/acs.nanolett.4c03672 · Cited by 4
Mattingly, T. J., McQueen, R. B., & Lin, P. (2021) · PharmacoEconomics · doi:10.1007/s40273-021-01079-6 · Cited by 4
“, labor, housing, legal), the growth of the aging population, long-term care services, and how health systems and governments incorporate items not typically covered by a patient’s health insurance [7, 8].”
BackgroundA Task-Optimized Approach for High-Accuracy Alzheimer’s Diagnosis from Handwriting DataPreprint
HosseiniNian, Z. S., Tajari, A., Behrouz Barati, B., & Baharlouei, S. (2024) · medRxiv · doi:10.1101/2024.12.17.24319146 · Cited by 3
McCage, S., Walker, K., Cornelius, T. M., Parker, R. A., Dams-O’Connor, K., Dickerson, B. C., Ritchie, C. S., Vranceanu, A., & Bannon, S. M. (2024) · JMIR Research Protocols · doi:10.2196/60382 · Cited by 2
“…and Alzheimer disease-related dementias (ADRDs) are conditions characterized by progressive declines in memory, language, behavior, and personality and produce early symptoms that include increased forgetfulness, communication challenges, and loss of recognition of places, time, and routines [1-3].”
Time value of informal care of people with alzheimer’s disease in Spain: a population-based analysis
Vilaplana‐Prieto, C., & Oliva, J. (2024) · The European Journal of Health Economics · doi:10.1007/s10198-024-01713-y · Cited by 5
Heat shock protein and Alzheimer’s disease: an updated systematic review
Raza, H., Ali, A., Kumar, A., Adnan, F., Shah, S. A. W., Ghazanfar, S., Roshan, F. N. U., Shamim, Z., Opare, A. D., & Tanveer, F. S. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002887 · Cited by 2
“Subsequently, all endeavors aimed at discovering a viable disease-modifying therapy were of considerable importance [ 3 ] .”
Cesana, B. M., Poptsi, E., Tsolaki, M., Bergh, S., Fabbo, A., Froelich, L., Jori, M. C., & Defanti, C. A. (2025) · NeuroSci · doi:10.3390/neurosci6020045 · Cited by 3
Tabish, M., Malik, I., Ansarullah, S. I., & Alshahrani, A. (2025) · Journal of Disability Research · doi:10.57197/jdr-2025-0735 · Cited by 2
Caregivers' perspectives on lecanemab use for Alzheimer's disease: A national survey in China
Liu, S., Fan, S., Gan, J., Liao, W., Chen, Q., Li, X., Zhang, J., Chen, X., & Ji, Y. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70680 · Cited by 3
Robles, V., Valentí, M., Mendibe, M., Hidalgo, Á., Albamonte, F., Berrocoso, E., Lara, M., Calvo, R., López, C., Deshpande, O., et al. (2025) · Neuroscience Applied · doi:10.1016/j.nsa.2025.106879 · Cited by 3
Gerritsen, D. L., Bossche, M. J. A. V. D., Atri, A., Chumki, S. R., Cummings, J. L., Declercq, I., Forester, B. P., Gastiazoro, M. P., Khoury, R., Michael, M. C., et al. (2026) · International Psychogeriatrics · doi:10.1016/j.inpsyc.2026.100241 · Cited by 2
Self-citationMultimorbidity in neurodegenerative diseases: a network analysis
Amini, M., Bagheri, A., Paulus, M. P., & Delen, D. (2024) · Informatics for Health and Social Care · doi:10.1080/17538157.2024.2405869 · Cited by 4
“10,11 Understanding the most prevalent complications of NDs can lead to better resource allocations, more effective preventive screenings, and improved quality of care.”
Expanding the Applicability of Cognitive Charts to the Entire Age Span
Gourdeau, C., Légaré-Baribeau, M.-P., Bernier, P., & Laforce, R. J. (2025) · Brain Sciences · doi:10.3390/brainsci15040327 · Cited by 2
Grand Challenges and Perspectives in Biomedical Analysis and Diagnostics
Cheng, Q. J. (2021) · Frontiers in Analytical Science · doi:10.3389/frans.2021.700386 · Cited by 2
Historical efforts to develop 99mTc-based amyloid plaque targeting radiotracers
Takalloobanafshi, G., Kukreja, A., & Hicks, J. W. (2022) · Frontiers in Nuclear Medicine · doi:10.3389/fnume.2022.963698 · Cited by 2
Paquete, A. T., Martins, R., Kotsopoulos, N., Urbich, M., Green, C., & Connolly, M. P. (2022) · The Journal of the Economics of Ageing · doi:10.1016/j.jeoa.2022.100413 · Cited by 2
Diseases with the highest mortality
Avilés‐Gaxiola, S., Criollo-Mendoza, M. S., García-Carrasco, M., Gutiérrez‐Grijalva, E. P., García-Aguiar, I., & Heredia, J. B. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-90390-5.00001-3 · Cited by 2
The impact of dementia family caregiving on adolescent well-being: A scoping review
Kates, J., Pogorzelska‐Maziarz, M., Uppal, M., & Gerolamo, A. M. (2023) · Dementia · doi:10.1177/14713012231161385 · Cited by 2
“financial impact of Alzheimer’s disease and related dementias (ADRD) on households and the economy is substantial (El-Hayek et al., 2019); however, there are also intangible costs that are absent from studies estimating the socioeconomic implications of ADRD (Colucci et al.”
BackgroundBhratee, A., Kumar, M., Alam, M. R., Anand, P., & Singh, S. (2023) · Current Pharmacology Reports · doi:10.1007/s40495-023-00325-z · Cited by 2
“Dementia, including Alzheimer’s disease (AD), is the leading cause of impairment and dependency among the elderly, resulting in significant negative socioeconomic consequences [74].”
BackgroundKwok, I., Lattie, E. G., Yang, D., Summers, A., Cotten, P. D., Leong, C. A., & Moskowitz, J. T. (2024) · JMIR Formative Research · doi:10.2196/50234 · Cited by 2
“However, in more advanced stages of the disease, caregivers often have to cope with agitation, aggression, and wandering [7] while shouldering an increasing logistical and financial burden of coordinating care [8,9].”
BackgroundResearch Funding for Women's Health: Modeling Societal Impact
Baird, M., Zaber, M. A., Chen, A. I.-A., Dick, A. W., Bird, C. E., Waymouth, M., Gahlon, G., Quigley, D. D., Al-Ibrahim, H., & Frank, L. B. (2021) · RAND Corporation eBooks · doi:10.7249/rra708-4 · Cited by 4
Gopalakrishnan, A., Prabhu, D. B., & Pichumani, M. (2025) · Next Nanotechnology · doi:10.1016/j.nxnano.2025.100266 · Cited by 2
Unpaid dementia carers: a scoping review of the caregiving trajectory and changing short break needs
Caulfield, M., & Seddon, D. (2025) · Frontiers in Health Services · doi:10.3389/frhs.2025.1583975 · Cited by 1
Cárdenas, M. K., Anza‐Ramirez, C., Bernabé‐Ortiz, A., Custodio, N., Montesinos, R., Miranda, J. J., Re, M. D., Belón-Hercilla, V., Lazo‐Porras, M., Hawkins, J. L., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2025-107142 · Cited by 1
Dixon, P., & Anderson, E. L. (2025) · Cost Effectiveness and Resource Allocation · doi:10.1186/s12962-025-00684-y · Cited by 2
Rao, R. V., Boyd, A., Okada, S., Lipa, W., Kelly, L., Coward, C., Bredesen, A. L., Gregory, J., & Bredesen, D. E. (2025) · Brain Sciences · doi:10.3390/brainsci16010002 · Cited by 1
“Alzheimer’s disease (AD), a neurodegenerative disorder marked by progressive cognitive decline, remains a leading cause of morbidity in aging populations worldwide [1–3].”
Vermeulen, R. J., Rikkert, M. O., Handels, R. L. H., Haraldsen, I., Renvall, H., Rossini, P. M., Marra, C., Maestú, F., Rovers, M. M., & Govers, T. M. (2026) · GeroScience · doi:10.1007/s11357-025-02032-7 · Cited by 2
Xu, J., Zhang, X., Cui, Y., Zheng, Q., Wang, C. Y., Kang, Y. Q., Xing, L., Zhang, X., Qin, Y., Yuan, K., et al. (2026) · Aging & Mental Health · doi:10.1080/13607863.2026.2632752 · Cited by 1
“As the most prevalent form of dementia in adults, AD is characterized by its heterogeneous neurodegenerative nature, posing substantial burdens on patients, families, and healthcare systems alike (El-Hayek et al., 2019).”
Depression in neurodegenerative disease: neurobiological mechanisms and emerging treatments
Costello, H., Reeves, S., Glue, P., Young, A. H., & Howard, R. J. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03728-8 · Cited by 1
“Depression in these conditions predicts greater disease progression, poorer quality of life, higher mortality [3, 4], and doubles healthcare costs [5 – 8].”
Long-Term Income and Productivity Losses in Individuals With Early-Onset Dementia
Kivisild, A., Aaltonen, M., Aho, K., Heikkinen, S. V., Lehtonen, A., Leppänen, L., Rinnankoski, I., Tervonen, L., Soppela, H., Haapasalo, A., et al. (2026) · Neurology · doi:10.1212/wnl.0000000000218268 · Cited by 1
The quid pro quo of blood pressure control and dementia
Ryan, J. L., & Ernst, M. E. (2023) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(23)00159-9 · Cited by 1
Family Conflict in Dementia Caregiving: Maintaining Research Ethics and Integrity
Norwood, K., & Webster, M. (2023) · Emerald Group Publishing Limited eBooks · doi:10.1108/s2398-601820230000009004 · Cited by 1
Caffeine Intake and Cognitive Function Among US Adults Aged 60+: Insights From NHANES 2011−2014
Wang, X., Li, M., & Zhang, M. (2025) · Journal of Human Nutrition and Dietetics · doi:10.1111/jhn.70090 · Cited by 1
Societal Impact of Research Funding for Women's Health in Coronary Artery Disease
Baird, M., Zaber, M. A., Dick, A. W., Bird, C. E., Chen, A. I.-A., Waymouth, M., Gahlon, G., Quigley, D. D., Al-Ibrahim, H., & Frank, L. B. (2021) · RAND Corporation eBooks · doi:10.7249/rra708-2 · Cited by 1
“The results can help establish the value of new interventions by addressing which stakeholders and which societal payers are affected (El-Hayek et al., 2019).”
BackgroundThe Role of Polyphenols in the Treatment of Alzheimer's Disease: Narrative Review
Alattiya, R. H., Tarish, F. K., Hashim, L. L., & Hussain, S. A. (2021) · Al-Rafidain Journal of Medical Sciences · doi:10.54133/ajms.v1i.31 · Cited by 3
Comas‐Herrera, A. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780192859808.003.0009 · Cited by 3
Cotton, K., & Verghese, J. (2024) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2024.105415 · Cited by 1
Connecting genomic and proteomic signatures of amyloid burden in the brainPreprint
Puerta, R., de Rojas, I., García‐González, P., Olivé, C., Sotolongo‐Grau, Ó., García‐Sánchez, A., García‐Gutiérrez, F., Montrreal, L., Tartari, J. P., Sanabria, Á., et al. (2024) · medRxiv · doi:10.1101/2024.09.06.24313124 · Cited by 1
Increase in health care costs due to aorta calcification and low ABI in older men
Taşçı, İ., & Naharcı, M. İ. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.02.019
Baboo, G. K., Prasad, R., Mahajan, P., & Baths, V. (2021) · Research Square · doi:10.21203/rs.3.rs-277919/v1
THE INFLUENCE OF MITOCHONDRIA IN ALZHEIMER DISEASE AND POSSIBLE ALTERNATIVE THERAPIES
(2021) · International Journal of Neuroscience Research · doi:10.28933/ijnr-2021-04-0606
(2020) · Emerald Group Publishing Limited eBooks · doi:10.1108/978-1-83867-691-920201009
The Application of 3+1 Holistic Rehabilitation Nursing in Patients with Alzheimer’s Disease
Huang, M. (2022) · Journal of Clinical and Nursing Research · doi:10.26689/jcnr.v6i2.3609
“Direct and indirect costs, which include family care expenses and work-related costs, increase before and after the diagnosis of AD [4] .”
BackgroundBaboo, G. K., Prasad, R., Mahajan, P., & Baths, V. (2022) · Annals of Neurosciences · doi:10.1177/09727531221117633 · Cited by 1
“Phys Rev E Stat Phys Plasmas Fluids Relat Interdiscip Topics July 26, 2002; 66(1): 16128, https://link.”
InfluentialMar, J., Ibarrondo, O., Larrañaga, I., Mar‐Barrutia, L., & Soto‐Gordoa, M. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01111-7
“The same barrier exists in the USA between the financing of healthcare by Medicare or private insurers and that of long-term care that falls largely on families themselves (informal care and out-of-pocket costs) [45, 51].”
BackgroundDrew, C. J. G., & Busse, M. E. (2022) · International review of neurobiology · doi:10.1016/bs.irn.2022.09.006 · Cited by 3
Metadata
- Authors
- El-Hayek, Y. H., Wiley, R. E., Khoury, C. P., Daya, R. P., Ballard, C., Evans, A. R., Karran, M., Molinuevo, J. L., Norton, M., & Atri, A.
- Affiliations
- Shift Health, Toronto, ON, Canada
- McMaster University (CA)
- University of Exeter (GB)
- Alzheimer’s Research UK (GB)
- Barcelonaβeta Brain Research Center, Barcelona, Spain
- Brigham and Women's Hospital (US)
- Corresponding author
- Atri, Alireza
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2019-07-23
- Volume
- 70
- Issue
- 2
- Pages
- 323-341
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- PMC
- PMC6700654
- OpenAlex
- W2954682095
- Cited by
- 216
- References
- 132
- Citations by year
- 2026: 10 · 2025: 33 · 2024: 28 · 2023: 34 · 2022: 47 · 2021: 40 · 2020: 23 · 2019: 1
- FWCI
- 4.66
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Alzheimer s Disease (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Royal Devon and Exeter Research Repository (Royal Devon and Exeter) (submittedVersion, cc-by-nc)
- Funders
- F. Hoffmann-La Roche
- National Institute on Aging (P30AG019610)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- Alzheimer's disease, related dementias
- MeSH terms
- Stakeholder Participation, Alzheimer Disease, Dementia, Humans, Socioeconomic Factors, Global Health, Health Care Costs, Cost of Illness
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.